Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Ionis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$944.00M

Latest Revenue (Q)

$246.09M

Main Segment (Y)

Commercial Member

Ionis Pharmaceuticals Revenue by Period

Ionis Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$944.00M	33.87%
2024-12-31	$705.14M	-10.48%
2023-12-31	$787.65M	34.10%
2022-12-31	$587.37M	-27.53%
2021-12-31	$810.46M	11.13%
2020-12-31	$729.26M	-35.04%
2019-12-31	$1.12B	87.20%
2018-12-31	$599.67M	16.63%
2017-12-31	$514.18M	37.93%
2016-12-31	$372.78M	31.40%
2015-12-31	$283.70M	32.47%
2014-12-31	$214.16M	45.41%
2013-12-31	$147.28M	44.33%
2012-12-31	$102.05M	2.99%
2011-12-31	$99.09M	-8.65%
2010-12-31	$108.47M	-10.80%
2009-12-31	$121.60M	13.44%
2008-12-31	$107.19M	83.72%
2007-12-31	$58.34M	292.65%
2006-12-31	$14.86M	-62.98%
2005-12-31	$40.13M	-5.84%
2004-12-31	$42.62M	-14.73%
2003-12-31	$49.99M	-37.65%
2002-12-31	$80.18M	50.51%
2001-12-31	$53.27M	43.00%
2000-12-31	$37.26M	9.90%
1999-12-31	$33.90M	-13.52%
1998-12-31	$39.20M	19.88%
1997-12-31	$32.70M	44.05%
1996-12-31	$22.70M	74.62%
1995-12-31	$13.00M	28.71%
1994-12-31	$10.10M	-16.53%
1993-12-31	$12.10M	-

Ionis Pharmaceuticals generated $944.00M in revenue during NA 2025, up 33.87% compared to the previous quarter, and up 129.45% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2026-03-31	$246.09M	21.23%
2025-12-31	$203.00M	29.53%
2025-10-28	$156.72M	-65.33%
2025-06-30	$452.05M	243.47%
2025-03-31	$131.61M	-41.91%
2024-12-31	$226.58M	69.32%
2024-09-30	$133.81M	-40.59%
2024-06-30	$225.25M	88.50%
2024-03-31	$119.50M	-63.18%
2023-12-31	$324.50M	125.03%
2023-09-30	$144.21M	-23.46%
2023-06-30	$188.41M	44.35%
2023-03-31	$130.52M	-14.07%
2022-12-31	$151.89M	-4.93%
2022-09-30	$159.77M	19.42%
2022-06-30	$133.79M	-5.73%
2022-03-31	$141.92M	-67.75%
2021-12-31	$440.01M	230.60%
2021-09-30	$133.09M	5.84%
2021-06-30	$125.75M	12.67%
2021-03-31	$111.61M	-61.55%
2020-12-31	$290.28M	81.34%
2020-09-30	$160.08M	9.99%
2020-06-30	$145.54M	9.13%
2020-03-31	$133.37M	-72.99%
2019-12-31	$493.68M	194.05%
2019-09-30	$167.89M	2.49%
2019-06-30	$163.81M	-44.88%
2019-03-31	$297.21M	54.71%
2018-12-31	$192.12M	32.13%
2018-09-30	$145.40M	23.48%
2018-06-30	$117.75M	-18.47%
2018-03-31	$144.42M	-16.18%
2017-12-31	$172.30M	42.50%
2017-09-30	$120.91M	16.09%
2017-06-30	$104.15M	-5.58%
2017-03-31	$110.30M	-31.21%
2016-12-31	$160.35M	44.55%
2016-09-30	$110.93M	188.35%
2016-06-30	$38.47M	4.33%
2016-03-31	$36.87M	-28.50%
2015-12-31	$51.57M	4.99%
2015-09-30	$49.12M	-59.21%
2015-06-30	$120.43M	92.43%
2015-03-31	$62.58M	-26.25%
2014-12-31	$84.86M	92.59%
2014-09-30	$44.06M	-22.80%
2014-06-30	$57.08M	102.68%
2014-03-31	$28.16M	-33.35%
2013-12-31	$42.25M	79.14%
2013-09-30	$23.59M	-38.08%
2013-06-30	$38.09M	-12.15%
2013-03-31	$43.36M	118.19%
2012-12-31	$19.87M	71.30%
2012-09-30	$11.60M	-75.49%
2012-06-30	$47.34M	103.74%
2012-03-31	$23.23M	-28.29%
2011-12-31	$32.40M	56.44%
2011-09-30	$20.71M	-16.56%
2011-06-30	$24.82M	17.38%
2011-03-31	$21.15M	-19.96%
2010-12-31	$26.42M	-7.70%
2010-09-30	$28.62M	21.79%
2010-06-30	$23.50M	-21.46%
2010-03-31	$29.93M	-7.24%
2009-12-31	$32.26M	20.51%
2009-09-30	$26.77M	-13.62%
2009-06-30	$30.99M	-1.85%
2009-03-31	$31.58M	52.83%
2008-12-31	$20.66M	-35.87%
2008-09-30	$32.22M	-2.26%
2008-06-30	$32.96M	54.36%
2008-03-31	$21.35M	-13.64%
2007-12-31	$24.73M	-

Ionis Pharmaceuticals generated $246.09M in revenue during Q1 2026, up 21.23% compared to the previous quarter, and up 108.61% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue Breakdown

Ionis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Product	$115.31M	$34.19M	$34.91M	$30.05M	-
Commercial Member	$435.85M	-	-	-	-
Royalty	$285.53M	-	-	-	-
Collaborative Agreement Revenue	-	$332.65M	$352.66M	$207.22M	-
Commercial	-	$293.08M	$308.59M	$303.36M	$342.39M
Other Commercial	-	$56.78M	$68.21M	-	-
Other	-	$22.59M	-	-	-
Research and Development Revenue	-	$412.06M	$479.06M	$284.01M	-
SPINRAZA Royalties	-	$216.09M	$240.38M	-	-
Licensing and Other Royalties	-	-	$33.30M	$30.99M	$19.12M
Spinraza Royalties	-	-	-	$242.31M	$267.78M
Eplontersen Joint Development Revenue	-	-	-	$76.79M	-
TEGSEDI and WAYLIVRA	-	-	-	-	$55.50M
Research and Development Revenue Under Collaborative Agreements	-	-	-	-	$468.06M

Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Commercial Member (52.09%), Royalty (34.13%), and Product (13.78%).

Quarterly Revenue by Product

Product/Service	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23
Royalty	$58.32M	$75.72M	$75.69M	$69.95M	$64.17M	-	-	-	-	-	-
Commercial Member	$107.81M	$217.49M	$115.60M	$102.76M	-	-	-	-	-	-	-
Product	$42.95M	$64.25M	$31.79M	$19.27M	$17.07M	$8.92M	$8.19M	$20.15M	$8.29M	-	-
Collaborative Agreement Revenue	-	-	-	-	$45.03M	$146.24M	$44.88M	$141.52M	$179.14M	$44.17M	$91.01M
Commercial	-	-	-	-	$76.17M	$145.31M	$75.73M	$72.04M	$78.84M	$84.08M	$77.90M
TEGSEDI and WAYLIVRA	-	-	-	-	$5.71M	-	-	-	-	-	-
SPINRAZA Royalties	-	-	-	-	$48.01M	$102.14M	$57.21M	$56.74M	$112.11M	$67.25M	$61.01M
Research and Development Revenue	-	-	-	-	$55.44M	$200.76M	$58.08M	$153.21M	$245.66M	$60.13M	$110.51M
Other Commercial	-	-	-	-	$5.71M	$32.12M	$13.15M	$11.51M	$34.50M	$16.83M	$16.89M
Product Sales, Net	-	-	-	-	$6.29M	-	-	-	-	-	-
Licensing and Other Royalties	-	-	-	-	-	-	$4.23M	$3.32M	$13.71M	$8.54M	-
Eplontersen Joint Development Revenue	-	-	-	-	-	-	-	-	-	$15.96M	$19.50M

Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Commercial Member (51.56%), Royalty (27.89%), and Product (20.54%).

Ionis Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
BMRN	BioMarin Pharmaceutical	$3.22B	$766.21M
EXEL	Exelixis	$2.32B	$610.81M
MRNA	Moderna	$1.94B	$389.00M
GH	Guardant Health	$982.02M	$301.67M
MDGL	Madrigal Pharmaceuticals	$958.40M	$287.27M
IONS	Ionis Pharmaceuticals	$944.00M	$246.09M
BBIO	BridgeBio Pharma	$362.37M	$180.60M
ASND	Ascendis Pharma	$266.72M	$95.89M
ROIV	Roivant Sciences	$8.26M	$2.00M
RVMD	Revolution Medicines	-	-
SMMT	Summit Therapeutics	-	-

IONS Revenue FAQ

What is Ionis Pharmaceuticals’s yearly revenue?

Ionis Pharmaceuticals's yearly revenue for 2025 was $944M, representing an increase of 33.87% compared to 2024. The company's yearly revenue for 2024 was $705.14M, representing a decrease of -10.48% compared to 2023. IONS's yearly revenue for 2023 was $787.65M, representing an increase of 34.10% compared to 2022.

What is Ionis Pharmaceuticals’s quarterly revenue?

Ionis Pharmaceuticals's quarterly revenue for Q1 2026 was $246.09M, a 21.23% increase from the previous quarter (Q4 2025), and a 86.98% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $203M, a 29.53% increase from the previous quarter (Q3 2025), and a -10.41% decrease year-over-year (Q4 2024). IONS's quarterly revenue for Q3 2025 was $156.72M, a -65.33% decrease from the previous quarter (Q2 2025), and a 17.12% increase year-over-year (Q3 2024).

What is Ionis Pharmaceuticals’s revenue growth rate?

Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 19.85%, and for the last 5 years (2021-2025) was 16.48%.

What are Ionis Pharmaceuticals’s revenue streams?

Ionis Pharmaceuticals's revenue streams in c 25 are Product, Commercial Member, and Royalty. Product generated $115.32M in revenue, accounting 13.78% of the company's total revenue, up 237.29% year-over-year. Commercial Member generated $435.85M in revenue, accounting 52.09% of the company's total revenue Royalty generated $285.53M in revenue, accounting 34.13% of the company's total revenue

What is Ionis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Ionis Pharmaceuticals was Commercial Member. This segment made a revenue of $435.85M, representing 52.09% of the company's total revenue.